• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
ZHANG Yu, YAN Fang, XIAO Yibei. Development of VISTA in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2022, 53(4): 400-409. DOI: 10.11665/j.issn.1000-5048.20220403
Citation: ZHANG Yu, YAN Fang, XIAO Yibei. Development of VISTA in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2022, 53(4): 400-409. DOI: 10.11665/j.issn.1000-5048.20220403
shu

Development of VISTA in tumor immunotherapy

  • School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China

Funds: This study was supported by the National Natural Science Foundation of China (No.31970547) and the Natural Science Foundation of Jiangsu Province (No.BK20190552)
More Information
  • Received Date: February 22, 2022
  • Revised Date: June 03, 2022
    Graphical Abstract
    • Abstract
  • V-domain immunoglobulin suppressor of T-cell activation (VISTA) is a member of the B7 family that maintains homeostasis in T cells and myeloid cells.Blocking VISTA inhibits tumor development in in vitro and in vivo trials, and is an important target for tumor immunotherapy.This review focuses on its structural features, expression and biological functions in tumor microenvironment, summarizes the current stage of small molecule inhibitors and antibodies targeting VISTA, and discusses the research approaches.It aims to provide a rationale for subsequent study on VISTA and the development of related immune checkpoint antitumor drugs.
    • FullText(HTML)
    • References (63)
  • [1]
    . Lancet Oncol，2017，18（11）：e632.
    [2]
    Kruger S，Ilmer M，Kobold S，et al. Advances in cancer immunotherapy 2019-latest trends［J］. J Exp Clin Cancer Res，2019，38（1）：268.
    [3]
    Hodi FS，Chiarion-Sileni V，Gonzalez R，et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma （CheckMate 067）：4-year outcomes of a multicentre，randomised，phase 3 trial［J］. Lancet Oncol，2018，19（11）：1480-1492.
    [4]
    Kakavand H，Jackett LA，Menzies AM，et al. Negative immune checkpoint regulation by VISTA：a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients［J］. Mod Pathol，2017，30（12）：1666-1676.
    [5]
    Gao JJ，Ward JF，Pettaway CA，et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer［J］. Nat Med，2017，23（5）：551-555.
    [6]
    Wang L，Rubinstein R，Lines JL，et al. VISTA，a novel mouse Ig superfamily ligand that negatively regulates T cell responses［J］. J Exp Med，2011，208（3）：577-592.
    [7]
    Lines JL，Pantazi E，Mak J，et al. VISTA is an immune checkpoint molecule for human T cells［J］. Cancer Res，2014，74（7）：1924-1932.
    [8]
    ElTanbouly MA，Zhao YD，Nowak E，et al. VISTA is a checkpoint regulator for na?ve T cell quiescence and peripheral tolerance［J］. Science，2020，367（6475）：eaay0524.
    [9]
    Flies DB，Wang SD，Xu HY，et al. Cutting edge：a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models［J］. J Immunol，2011，187（4）：1537-1541.
    [10]
    Mehta N，Maddineni S，Mathews II，et al. Structure and functional binding epitope of V-domain ig suppressor of T cell activation ［J］. Cell Rep，2019，28（10）：2509-2516.e5.
    [11]
    Liu J，Yuan Y，Chen WN，et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses［J］. Proc Natl Acad Sci U S A，2015，112（21）：6682-6687.
    [12]
    Wang JH，Wu GP，Manick B，et al. VSIG-3 as a ligand of VISTA inhibits human T-cell function［J］. Immunology，2019，156（1）：74-85.
    [13]
    Johnston RJ，Su LJ，Pinckney J，et al. VISTA is an acidic pH-selective ligand for PSGL-1［J］. Nature，2019，574（7779）：565-570.
    [14]
    Harada H，Suzu S，Hayashi Y，et al. BT-IgSF，a novel immunoglobulin superfamily protein，functions as a cell adhesion molecule［J］. J Cell Physiol，2005，204（3）：919-926.
    [15]
    Tinoco R，Carrette F，Barraza ML，et al. PSGL-1 is an immune checkpoint regulator that promotes T cell exhaustion ［J］. Immunity，2016，44（5）：1190-1203.
    [16]
    Yang W，Padkj?r SB，Wang JS，et al. Construction of a versatile expression library for all human single-pass transmembrane proteins for receptor pairings by high throughput screening［J］. J Biotechnol，2017，260：18-30.
    [17]
    Wu T，Dai Y. Tumor microenvironment and therapeutic response［J］. Cancer Lett，2017，387：61-68.
    [18]
    Kuklinski LF，Yan SF，Li ZZ，et al. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival［J］. Cancer Immunol Immunother，2018，67（7）：1113-1121.
    [19]
    le Mercier I，Chen WN，Lines JL，et al. VISTA regulates the development of protective antitumor immunity ［J］. Cancer Res，2014，74（7）：1933-1944.
    [20]
    Xu WW，Dong J，Zheng YW，et al. Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression［J］. Cancer Immunol Res，2019，7（9）：1497-1510.
    [21]
    Broughton TWK，ElTanbouly MA，Schaafsma E，et al. Defining the signature of VISTA on myeloid cell chemokine responsiveness［J］. Front Immunol，2019，10：2641.
    [22]
    Nowak EC，Lines JL，Varn FS，et al. Immunoregulatory functions of VISTA［J］. Immunol Rev，2017，276（1）：66-79.
    [23]
    Huang X，Zhang XZ，Li EL，et al. VISTA：an immune regulatory protein checking tumor and immune cells in cancer immunotherapy［J］. J Hematol Oncol，2020，13（1）：83.
    [24]
    Rosenbaum SR，Knecht M，Mollaee M，et al. FOXD3 regulates VISTA expression in melanoma［J］ Cell Rep，2020，30（2）：510-524.e6.
    [25]
    Hong SJ，Yuan Q，Xia HZ，et al. Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy［J］. Protein Cell，2019，10（11）：840-845.
    [26]
    Muller S，Lai WV，Adusumilli PS，et al. V-domain Ig-containing suppressor of T-cell activation （VISTA），a potentially targetable immune checkpoint molecule，is highly expressed in epithelioid malignant pleural mesothelioma［J］. Mod Pathol，2020，33（2）：303-311.
    [27]
    Villarroel-Espindola F，Yu XQ，Datar I，et al. Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer ［J］. Clin Cancer Res，2018，24（7）：1562-1573.
    [28]
    Hernandez-Martinez JM，Vergara E，Zatarain-Barrón ZL，et al. VISTA/PD-1H：a potential target for non-small cell lung cancer immunotherapy［J］. J Thorac Dis，2018，10（12）：6378-6382.
    [29]
    Ding A，Villarroel-Espindola F，Ducler A，et al. Abstract 5525：VISTA/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancer［C］//Immunology. American Association for Cancer Research，2020：5525.
    [30]
    Zong LJ，Zhang M，Wang WZ，et al. PD-L1，B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia［J］. Histopathology，2019，75（3）：421-430.
    [31]
    Mulati K，Hamanishi J，Matsumura N，et al. VISTA expressed in tumour cells regulates T cell function［J］. Br J Cancer，2019，120（1）：115-127.
    [32]
    Liao H，Zhu HM，Liu SL，et al. Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer［J］. Oncol Lett，2018，16（3）：3465-3472.
    [33]
    Zong LJ，Zhou YC，Zhang M，et al. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer［J］. Cancer Immunol Immunother，2020，69（1）：33-42.
    [34]
    B?ger C，Behrens HM，Krüger S，et al. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1：a future perspective for a combined gastric cancer therapy［J］？ Oncoimmunology，2017，6（4）：e1293215.
    [35]
    Deng J，Li JN，Sarde A，et al. Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment［J］. Cancer Immunol Res，2019，7（7）：1079-1090.
    [36]
    Mahoney KM，Freeman GJ. Acidity changes immunology：a new VISTA pathway［J］. Nat Immunol，2020，21（1）：13-16.
    [37]
    Yuan L，Tatineni J，Mahoney KM，et al. VISTA：a mediator of quiescence and a promising target in cancer immunotherapy［J］. Trends Immunol，2021，42（3）：209-227.
    [38]
    Sasikumar PGN，Ramachandra M，Naremadde-palli SSS.
    1，3，
    4-oxadiazole and 1，3，4-thiadiazole derivatives as immunomo-dulators：
    CA2922655［P］. 2016-02-26［2022-02-22］.
    [39]
    Li K，Tian HQ. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy［J］. J Drug Target，2019，27（3）：244-256.
    [40]
    Musielak B，Kocik J，Skalniak L，et al. CA-170—A potent small-molecule PD-L1 inhibitor or not［J］？ Molecules，2019，24（15）：2804.
    [41]
    Gabr MT，Gambhir SS. Discovery and optimization of small-molecule ligands for V-domain ig suppressor of T-cell activation （VISTA）［J］. J Am Chem Soc，2020，142（38）：16194-16198.
    [42]
    Snyder LA，Powers G，Sepulveda MA，et al. Anti-VISTA antibodies and fragments：
    US11009509［P］. 2021-05-18［2022-02-22］.
    [43]
    Melero I，Gomez-Roca C，Ferre P，et al. 315 W0180 novel anti-VISTA antibody：rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody［C］//Regular and young investigator award abstracts. BMJ Publishing Group Ltd，2020：8.
    [44]
    Boyd-Kirkup JD，Thakkar D，Paszkiewicz K，et al. Abstract 1729：Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD002，a novel anti-VISTA neutralizing antibody［C］//Immunology. American Association for Cancer Research，2018：1729.
    [45]
    Johnston，RJ. Five Prime Therapeutics Inc. Antibodies binding to VISTA at acidic pH：
    CA3092589［P］. 2020-08-30［2022-02-22］.
    [46]
    Mehta N，Maddineni S，Kelly RL，et al. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA［J］. Sci Rep，2020，10（1）：15171.
    [47]
    Scott F，Wichmann C，Burvenich I，et al. 324 Preclinical evaluation of anti-VISTA antibody CI-8993 in a syngeneic huVISTA-KI model［J］. J Immunother Cancer，2021，9（Suppl 2）：A349.
    [48]
    Thakkar D，Paliwal S，Dharmadhikari B，et al. Rationally targeted anti-VISTA antibody that blockades the C-C′ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner［J］. J Immunother Cancer，2022，10（2）：e003382.
    [49]
    DiMascio L，Thakkar D，Gandhi N，et al. HMBD-002 is a novel，neutralizing，anti-VISTA antibody exhibiting strong preclinical efficacy and safety，being developed as a monotherapy and in combination with pembrolizumab［J］. J Clin Oncol，2021，39（15_suppl）：e14569.
    [50]
    Liu C，Seeram NP，Ma H. Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development：a review［J］. Cancer Cell Int，2021，21（1）：239.
    [51]
    Lequin RM. Enzyme immunoassay （EIA）/enzyme-linked immunosorbent assay （ELISA）［J］. Clin Chem，2005，51（12）：2415-2418.
    [52]
    Cauchon E，Liu S，Percival MD，et al. Development of a homogeneous immunoassay for the detection of angiotensin I in plasma using AlphaLISA acceptor beads technology［J］. Anal Biochem，2009，388（1）：134-139.
    [53]
    Olaru A，Bala C，Jaffrezic-Renault N，et al. Surface plasmon resonance （SPR） biosensors in pharmaceutical analysis［J］. Crit Rev Anal Chem，2015，45（2）：97-105.
    [54]
    Concepcion J，Witte K，Wartchow C，et al. Label-free detection of biomolecular interactions using BioLayer interferometry for kinetic characterization［J］. Comb Chem High Throughput Screen，2009，12（8）：791-800.
    [55]
    Ghai R，Falconer RJ，Collins BM. Applications of isothermal titration calorimetry in pure and applied research：survey of the literature from 2010［J］. J Mol Recognit，2012，25（1）：32-52.
    [56]
    Wienken CJ，Baaske P，Rothbauer U，et al. Protein-binding assays in biological liquids using microscale thermophoresis［J］. Nat Commun，2010，1：100.
    [57]
    Babaoglu K，Shoichet BK. Deconstructing fragment-based inhibitor discovery［J］. Nat Chem Biol，2006，2（12）：720-723.
    [58]
    Musielak B，Janczyk W，Rodriguez I，et al. Competition NMR for detection of hit/lead inhibitors of protein-protein interactions［J］. Molecules，2020，25（13）：3017.
    [59]
    Versteven M，van den Bergh JMJ，Broos K，et al. A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches［J］. Oncotarget，2018，9（45）：27797-27808.
    [60]
    Abraham RT，Weiss A. Jurkat T cells and development of the T-cell receptor signalling paradigm［J］. Nat Rev Immunol，2004，4（4）：301-308.
    [61]
    Brusa D，Serra S，Coscia M，et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia［J］. Haematologica，2013，98（6）：953-963.
    [62]
    Wang MN，Yao LC，Cheng MS，et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy［J］. FASEB J，2018，32（3）：1537-1549.
    [63]
    de la Rochere P，Guil-Luna S，Decaudin D，et al. Humanized mice for the study of immuno-oncology［J］. Trends Immunol，2018，39（9）：748-763.
    • Related Articles

  • Related Articles

    [1]YANG Nan, ZHANG Xiao, LYU Hui, HUO Meirong, XU Wei. Advances in immune checkpoint inhibitors combined with other treatments[J]. Journal of China Pharmaceutical University, 2023, 54(2): 131-140. DOI: 10.11665/j.issn.1000-5048.20221028002
    [2]YAO Zheng, LI Zihan, GAO Liming, HU Xing, CHEN Yan, PAN Wenqi, LI Qian. Advances of research on CAR-T cell immunotherapy for solid tumors[J]. Journal of China Pharmaceutical University, 2021, 52(4): 496-504. DOI: 10.11665/j.issn.1000-5048.20210413
    [3]BU Hong, ZHOU Jinpei, ZHANG Huibin. Research progress of mitogen-activated protein kinase interacting kinases inhibitors in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2021, 52(4): 410-421. DOI: 10.11665/j.issn.1000-5048.20210403
    [4]CHEN Wenting, LIU Jun. Advances in research on immune checkpoint and its inhibitors in glioma[J]. Journal of China Pharmaceutical University, 2021, 52(1): 104-112. DOI: 10.11665/j.issn.1000-5048.20210115
    [5]XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
    [6]LI Fang, XIN Junbo, SHI Qin, MAO Chengqiong. Advances in near infrared photoimmunotherapy of tumor[J]. Journal of China Pharmaceutical University, 2020, 51(6): 664-674. DOI: 10.11665/j.issn.1000-5048.20200604
    [7]TIAN Jiping, ZHANG Jian, ZHOU Jinpei, ZHANG Huibin. Advances in small molecule inhibitors of PD-1/PD-L1 immune checkpoint pathway[J]. Journal of China Pharmaceutical University, 2019, 50(1): 1-10. DOI: 10.11665/j.issn.1000-5048.20190101
    [8]ZHANG Rui, JIANG Tao, ZENG Tianzhu, YAO Wenbing, GAO Xiangdong, TIAN Hong. Advances of combined immunotherapy in tumor[J]. Journal of China Pharmaceutical University, 2018, 49(4): 383-391. DOI: 10.11665/j.issn.1000-5048.20180401
    [9]YANG Ruocong, DUAN Feipeng, CHAO Jiahong, TIAN Pengpeng, YAN Zhiyong, LI Shaojing. Advances of microRNA activity in innate immunity[J]. Journal of China Pharmaceutical University, 2017, 48(4): 396-406. DOI: 10.11665/j.issn.1000-5048.20170403
    [10]LIU Kejun, ZHANG Zhimin, RAN Ting, CHEN Hongli, LU Tao, CHEN Yadong. Advances in BET bromodomain protein inhibitors[J]. Journal of China Pharmaceutical University, 2015, 46(3): 264-271. DOI: 10.11665/j.issn.1000-5048.20150302

Catalog

    Get Citation
    PDF
    XML
    Article views (781) PDF downloads (845) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：297216

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return